These findings are consistent with our previous finding that steroid treatment activates NR3C1 target genes similarly between steroid-sensitive and steroid-resistant ALL patients [56], supporting the notion that resistance mechanisms are downstream—or independent—of steroid-induced NR3C1 transactivation. This evidence concerns the gene NR3C1 and acute lymphoblastic leukemia.